52 results
Page 2 of 3
6-K
EX-99.3
aplvg va4
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.3
kgheasl p2y69a
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.3
ob6fo0r6p 8lyco
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
424B5
51hpxp28nvehfp8z ja
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.2
ffehr 96flxpm4p97uvg
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
424B8
4givjb
19 Apr 21
Prospectus unintentially filed late
5:06pm
6-K
EX-1.1
0jffudrd8n423
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
6-K
EX-99.1
3346romgtzi1a xj
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
6-K
EX-99.2
cf13uplu966ibx3f3
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
6-K
EX-10.1
8q6x64
12 May 20
Current report (foreign)
12:04pm
6-K
EX-10.1
lapg rn4gz7
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
6-K
EX-10.1
cb1zzeqfo976kclnith
17 May 19
Current report (foreign)
5:20pm
424B5
43rlxeuq
17 May 19
Prospectus supplement for primary offering
5:19pm
424B5
df4goao6
27 Jun 18
Prospectus supplement for primary offering
9:30am
6-K
EX-1.1
kmc5afx636zv0 p10vh
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am